|
Name |
gibberellin A12(2-)
|
| Molecular Formula | C20H26O4-2 | |
| IUPAC Name* |
(1R,2S,3S,4R,8S,9S,12R)-4,8-dimethyl-13-methylidenetetracyclo[10.2.1.01,9.03,8]pentadecane-2,4-dicarboxylate
|
|
| SMILES |
C[C@@]12CCC[C@@]([C@H]1[C@@H]([C@]34[C@H]2CC[C@H](C3)C(=C)C4)C(=O)[O-])(C)C(=O)[O-]
|
|
| InChI |
InChI=1S/C20H28O4/c1-11-9-20-10-12(11)5-6-13(20)18(2)7-4-8-19(3,17(23)24)15(18)14(20)16(21)22/h12-15H,1,4-10H2,2-3H3,(H,21,22)(H,23,24)/p-2/t12-,13+,14-,15+,18+,19-,20+/m1/s1
|
|
| InChIKey |
UJFQJDAESQJXTG-UFUZVNNQSA-L
|
|
| Synonyms |
gibberellin A12(2-); GA12; C20 skeleton; C20-GA skeleton; C20-gibberellin skeleton; C20-GAs; CHEBI:58627; open lactone gibberrellin skeleton; Q27125924; 1beta,4a-dimethyl-8-methylidene-4aalpha,4bbeta-gibbane-1alpha,10beta-dicarboxylate; (1R,2S,3S,4R,8S,9S,12R)-4,8-dimethyl-13-methylidenetetracyclo[10.2.1.0(1,9).0(3,8)]pentadecane-2,4-dicarboxylate; (1R,2S,3S,4R,8S,9S,12R)-4,8-dimethyl-13-methylidenetetracyclo[10.2.1.01,9.03,8]pentadecane-2,4-dicarboxylate
|
|
| CAS | NA | |
| PubChem CID | 25244528 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 330.4 | ALogp: | 5.2 |
| HBD: | 0 | HBA: | 4 |
| Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 80.3 | Aromatic Rings: | 4 |
| Heavy Atoms: | 24 | QED Weighted: | 0.723 |
| Caco-2 Permeability: | -5.849 | MDCK Permeability: | 0.00002050 |
| Pgp-inhibitor: | 0.003 | Pgp-substrate: | 0.001 |
| Human Intestinal Absorption (HIA): | 0.013 | 20% Bioavailability (F20%): | 0.036 |
| 30% Bioavailability (F30%): | 0.005 |
| Blood-Brain-Barrier Penetration (BBB): | 0.775 | Plasma Protein Binding (PPB): | 85.46% |
| Volume Distribution (VD): | 0.271 | Fu: | 11.82% |
| CYP1A2-inhibitor: | 0.009 | CYP1A2-substrate: | 0.223 |
| CYP2C19-inhibitor: | 0.01 | CYP2C19-substrate: | 0.182 |
| CYP2C9-inhibitor: | 0.023 | CYP2C9-substrate: | 0.163 |
| CYP2D6-inhibitor: | 0.01 | CYP2D6-substrate: | 0.122 |
| CYP3A4-inhibitor: | 0.079 | CYP3A4-substrate: | 0.034 |
| Clearance (CL): | 0.683 | Half-life (T1/2): | 0.619 |
| hERG Blockers: | 0.01 | Human Hepatotoxicity (H-HT): | 0.418 |
| Drug-inuced Liver Injury (DILI): | 0.639 | AMES Toxicity: | 0.008 |
| Rat Oral Acute Toxicity: | 0.297 | Maximum Recommended Daily Dose: | 0.125 |
| Skin Sensitization: | 0.338 | Carcinogencity: | 0.527 |
| Eye Corrosion: | 0.68 | Eye Irritation: | 0.592 |
| Respiratory Toxicity: | 0.949 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002559 | ![]() |
0.773 | D07BSQ | ![]() |
0.265 | ||
| ENC002555 | ![]() |
0.613 | D02CJX | ![]() |
0.261 | ||
| ENC001071 | ![]() |
0.483 | D0KR5B | ![]() |
0.259 | ||
| ENC002558 | ![]() |
0.478 | D0X7HM | ![]() |
0.257 | ||
| ENC002554 | ![]() |
0.472 | D0I2SD | ![]() |
0.255 | ||
| ENC003145 | ![]() |
0.440 | D0F1UL | ![]() |
0.252 | ||
| ENC000794 | ![]() |
0.440 | D0B4RU | ![]() |
0.252 | ||
| ENC002541 | ![]() |
0.394 | D0X4RS | ![]() |
0.252 | ||
| ENC003143 | ![]() |
0.388 | D0IX6I | ![]() |
0.248 | ||
| ENC002542 | ![]() |
0.371 | D0Q6NZ | ![]() |
0.248 | ||